Merten Hommann
Overview
Explore the profile of Merten Hommann including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
35
Citations
733
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Frilling A, Clift A, Kaemmerer D, Steinkraus K, Schrader J, Wolter S, et al.
Ann Surg
. 2024 Dec;
PMID: 39676650
Objective: To describe the evolution of management strategies for neuroendocrine liver metastases (NE LM) and trends in patient outcomes over the preceding 3 decades. Summary Background Data: Liver metastases are...
2.
Kaemmerer D, Hommann M
Inn Med (Heidelb)
. 2024 Jul;
65(11):1147-1149.
PMID: 39019992
Life-threatening side effects of mistletoe therapy are mostly negated by physicians working in complementary medicine. This article reports on a case of life-threatening anaphylactic shock after carrying out mistletoe therapy....
3.
Wust M, Hommann M, Kunze A
Pathologie (Heidelb)
. 2023 Feb;
44(4):211.
PMID: 36820921
No abstract available.
4.
Kaemmerer D, Kunze A, Robiller F, Hommann M, Anlauf M
Clin Nucl Med
. 2021 Feb;
46(5):409-410.
PMID: 33630790
The presence of primary neuroendocrine tumors in the liver is still a matter of controversy. We present a case of a somatostatin-receptor-positive mass of the liver in the 68Ga-DOTATOC PET/CT....
5.
Kaemmerer D, Twrznik M, Kulkarni H, Horsch D, Sehner S, Baum R, et al.
Ann Surg
. 2020 Oct;
274(1):e45-e53.
PMID: 33030849
Objective: The aim of the study was to compare impact on survival after resection of primary tumors (PTs) after peptide receptor radionuclide therapy (PRRT). Background: PRRT is a highly effective...
6.
Alvarez M, Subramaniam P, Tang L, Grunn A, Aburi M, Rieckhof G, et al.
Nat Genet
. 2018 Jun;
50(7):979-989.
PMID: 29915428
We introduce and validate a new precision oncology framework for the systematic prioritization of drugs targeting mechanistic tumor dependencies in individual patients. Compounds are prioritized on the basis of their...
7.
Baum R, Kulkarni H, Singh A, Kaemmerer D, Mueller D, Prasad V, et al.
Oncotarget
. 2018 Apr;
9(24):16932-16950.
PMID: 29682195
Introduction: Peptide receptor radionuclide therapy (PRRT) of patients with somatostatin receptor expressing neuroendocrine neoplasms has shown promising results in clinical trials and a recently published phase III study. Methods: In...
8.
Wellner U, Lapshyn H, Bartsch D, Mintziras I, Hopt U, Wittel U, et al.
Int J Colorectal Dis
. 2016 Nov;
32(2):273-280.
PMID: 27815701
Purpose: The aim of this study was to assess intraoperative, postoperative, and oncologic outcome in patients undergoing laparoscopic distal pancreatectomy (LDP) versus open distal pancreatectomy (ODP) for benign and malignant...
9.
Kaemmerer D, Trager T, Hoffmeister M, Sipos B, Hommann M, Sanger J, et al.
Oncotarget
. 2015 Aug;
6(29):27566-79.
PMID: 26259237
Introduction: Somatostatin receptors (SSTR) are widely distributed in well-differentiated neuroendocrine neoplasms (NEN) and serve as primary targets for diagnostics and treatment. An overexpression of the chemokine receptor CXCR4, in contrast,...
10.
Kaemmerer D, Wirtz R, Fischer E, Hommann M, Sanger J, Prasad V, et al.
Pancreas
. 2015 Apr;
44(4):648-54.
PMID: 25872131
Objective: Gallium 68 somatostatin receptor (SSTR) positron emission tomography/computed tomography (PET/CT) is one of the most sensitive imaging methods for pancreatic neuroendocrine tumors. The aim of the study was to...